Tags

Type your tag names separated by a space and hit enter

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
Antiviral Res. 2020 07; 179:104820.AR

Abstract

SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 infection. 18F3 recognized conserved epitopes on SARS-CoV and SARS-CoV-2 RBDs, whereas 7B11 recognized epitopes on SARS-CoV RBD not fully conserved in SARS-CoV-2 RBD. The 18F3-recognizing epitopes on RBD did not overlap with the ACE2-binding sites, whereas those recognized by 7B11 were close to the ACE2-binding sites, explaining why 7B11 could, but 18F3 could not, block SARS-CoV or SARS-CoV-2 RBD binding to ACE2 receptor. Our study provides an alternative approach to prevent SARS-CoV-2 infection using anti-SARS-CoV nAbs.

Authors+Show Affiliations

Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA.Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA.Institute of Pathogen Biology and Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. Electronic address: sjiang@nybc.org.Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, 10065, USA. Electronic address: ldu@nybc.org.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32405117

Citation

Tai, Wanbo, et al. "Identification of SARS-CoV RBD-targeting Monoclonal Antibodies With Cross-reactive or Neutralizing Activity Against SARS-CoV-2." Antiviral Research, vol. 179, 2020, p. 104820.
Tai W, Zhang X, He Y, et al. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020;179:104820.
Tai, W., Zhang, X., He, Y., Jiang, S., & Du, L. (2020). Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Research, 179, 104820. https://doi.org/10.1016/j.antiviral.2020.104820
Tai W, et al. Identification of SARS-CoV RBD-targeting Monoclonal Antibodies With Cross-reactive or Neutralizing Activity Against SARS-CoV-2. Antiviral Res. 2020;179:104820. PubMed PMID: 32405117.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. AU - Tai,Wanbo, AU - Zhang,Xiujuan, AU - He,Yuxian, AU - Jiang,Shibo, AU - Du,Lanying, Y1 - 2020/05/13/ PY - 2020/04/04/received PY - 2020/05/03/revised PY - 2020/05/08/accepted PY - 2020/5/15/pubmed PY - 2020/6/24/medline PY - 2020/5/15/entrez KW - COVID-19 KW - Cross-neutralization KW - Neutralizing monoclonal antibodies KW - Receptor-binding domain KW - SARS-CoV KW - SARS-CoV-2 SP - 104820 EP - 104820 JF - Antiviral research JO - Antiviral Res VL - 179 N2 - SARS-CoV-2-caused COVID-19 cases are growing globally, calling for developing effective therapeutics to control the current pandemic. SARS-CoV-2 and SARS-CoV recognize angiotensin-converting enzyme 2 (ACE2) receptor via the receptor-binding domain (RBD). Here, we identified six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 infection. 18F3 recognized conserved epitopes on SARS-CoV and SARS-CoV-2 RBDs, whereas 7B11 recognized epitopes on SARS-CoV RBD not fully conserved in SARS-CoV-2 RBD. The 18F3-recognizing epitopes on RBD did not overlap with the ACE2-binding sites, whereas those recognized by 7B11 were close to the ACE2-binding sites, explaining why 7B11 could, but 18F3 could not, block SARS-CoV or SARS-CoV-2 RBD binding to ACE2 receptor. Our study provides an alternative approach to prevent SARS-CoV-2 infection using anti-SARS-CoV nAbs. SN - 1872-9096 UR - https://www.unboundmedicine.com/medline/citation/32405117/Identification_of_SARS_CoV_RBD_targeting_monoclonal_antibodies_with_cross_reactive_or_neutralizing_activity_against_SARS_CoV_2_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-3542(20)30234-5 DB - PRIME DP - Unbound Medicine ER -